INTRODUCTION
Acrylamido polyvinyl alcohol hydrogel microspheres (A-PVAM) has been available as an embolic agent since 2002, yet limited literature about its efficacy for uterine artery embolisation (UAE) for symptomatic leiomyoma is available worldwide. In this study, we present our local experience with the use of this embolic agent.
METHODS

Patient Selection Criteria
This retrospective study analysed data collected from 2009 to 2012. All patients who underwent UAE for symptomatic uterine leiomyoma(s) using A-PVAM (Bead Block Biocompatibles, Farnham, UK) during the study period were included. Those patients who did not undergo post-embolisation imaging were excluded. Patients who underwent UAE using other embolic agents, or for other purposes not related to symptomatic leiomyomas, like adenomyosis, postpartum haemorrhage, vascular malformation, etc, were excluded. Two patients who used A-PVAM together with polyvinyl alcohol (PVA) particles were also excluded. This retrospective study was exempted from approval by the ethics committee as this was a case series only.
Pre-and Post-embolisation Clinical Assessment
All patients were referred from the Department of Obstetrics and Gynaecology of Queen Mary Hospital, Hong Kong. They were categorised into two major symptom groups, namely, pressure symptoms and menorrhagia. Their symptoms were assessed clinically before and after the embolisation in outpatient clinics by gynaecologists. The clinical consultation notes were reviewed through electronic patient records. Before undertaking the procedures, these patients were referred to our departmental outpatient clinic and seen by interventional radiologists who reviewed the clinical history to rule out any contraindications to UAE 1 including current pregnancy, known or suspected gynaecological malignancy, current uterine or adnexal infection, history of allergy to contrast, coagulopathy, and renal failure. The radiologists also reviewed the pre-embolisation magnetic resonance imaging (MRI) scans for anatomical location of the leiomyomas. Those patients with intracavitary or cervical leiomyoma and pedunculated leiomyoma with narrow stalks were rejected for UAE. The procedure and potential complications were explained during the consultation.
After the procedure, the patient symptoms were reassessed by the gynaecologists. Any subsequent surgical treatment received or complications related to the procedure were reviewed. Their follow-up in the gynaecology clinic was ongoing at the time this manuscript was written. All the clinical consultation notes until 1 May 2014 were reviewed.
Pre-and Post-embolisation Magnetic
Resonance Imaging Assessment
All patients had MRI of the pelvis before and after embolisation to assess the volume of the uterus and largest leiomyoma (calculated by the formula: height x length x width x 0.523). The MRI was reported by at least one radiology specialist who was not involved in the embolisation procedures. The percentage reductions in the volumes of the uterus and largest leiomyoma were calculated. Characteristics of the uterine leiomyomas including numbers, location, as well as preand post-embolisation signal intensity change were also recorded. Necrosis was defined as lack of enhancement of leiomyoma, or new T1-weighted hyperintense signal suggesting haemorrhagic infarction, or new T2-weighted hyperintense signal suggestive of liquefactive necrosis.
結論：雖然本研究的病例數目有限，但也證明A-PVAM用以子宮肌瘤動脈栓塞術治療效果積極的機
率高。未來對於包括A-PVAM在內的子宮動脈栓塞術新型栓塞劑的進一步研究會很有用。
Embolisation Procedures
All embolisation procedures were performed by two radiologists who were interventional radiology specialists and trainers at the Hong Kong College of Radiologists. The procedures were performed under deep sedation induced by anaesthetists. Vascular access was achieved by bilateral or single common femoral puncture followed by insertion of 5-French (5Fr) vascular sheath. Angiography of internal iliac artery and subsequent uterine artery on each side was performed with either angiocatheter 4Fr Cobra 1 or Simmons Sidewinder II with hydrophilic guidewire, and further super-selective catheterization of the uterine artery with or without coaxial micro-catheter system, depending on the size of the uterine artery. Different sizes of A-PVAM including 300 to 500 μm, 500 to 700 μm, and 700 to 900 μm were used, according to the size of the uterine artery. The procedures were performed according to the recommended protocol provided by the manufacturing company. About 5 ml of contrast was used to dilute the A-PVAM to obtain a 50% contrast and 50% A-PVAM saline solution mix. The A-PVAM suspension was injected from the syringe under fluoroscopic visualisation using a slow pulsatile action, while observing the contrast flow rate under real-time fluoroscopic screening to prevent any backflow. Additional injections of A-PVAM of the same size or larger size were given until the radiological endpoint was reached, corresponding to an angiographic image of a patent horizontal segment with stagnant flow in the ascending segment of the uterine artery (Figures 1 to 4) . The same procedures were performed on the contralateral side with a new set of catheter and guidewire. In one patient, only right UAE was performed as the left uterine artery could not be catheterized despite repeated attempts by both radiologists.
RESULTS
Patient Baseline Characteristics
A total of five patients were included in this study. The mean age was 43 years (range, 37-53 years). Three of the patients mainly presented with pressure symptoms (60%), one with menorrhagia (20%), and one was suffering severely from both pressure and menorrhagia symptoms (20%). Three patients had undergone previous myomectomy.
Pre-embolisation Magnetic Resonance Imaging Characteristics
All patients had more than 10 uterine leiomyomas.
Three out of five patients had uterine leiomyomas with subserosal, intramural, and submucosal components. One patient had intramural leiomyomas only, while one patient had both intramural and subserosal leiomyomas. The mean uterine volume was 685.4 ml, 
Post-embolisation Magnetic Resonance Imaging Characteristics
All patients showed reduction in the volumes of uterus and dominant leiomyoma. The mean volume reduction in the dominant leiomyoma was 45.8% (range, 18.2%-78.8%), and the mean uterine volume reduction was 31.4% (range, 12.8%-53.5%). Post-embolisation scans of all patients showed necrosis of the leiomyomas.
In the patient who underwent only unilateral UAE, uterine volume reduction was 25.6%, and volume reduction in the dominant leiomyoma was 18.2%.
Clinical Outcomes
All patients had clinical improvement in their pressure and / or menorrhagia symptoms. One patient who had bilateral UAE underwent subsequent myomectomy despite reduction of uterine volume, because she continued to suffer from urinary frequency after UAE. She had uterine volume reduction of 32% and dominant fibroid reduction of 50%, yet her uterus size after UAE corresponded to that of an 18-week pregnant uterus. Her uterus size was static on MRI and ultrasound after UAE until before surgery. 
Procedure-related Complications
DISCUSSION
Uterine leiomyoma is a very common gynaecological condition. The lifetime risk for a woman over the age of 45 years of having leiomyomas is more than 60%.
2
Patients with uterine leiomyoma commonly present with menorrhagia, pain, and urinary symptoms. 3 Although hysterectomy has been considered the definitive treatment, many uterus-conserving treatments have been widely used or are now being investigated. The non-surgical / minimally invasive surgical treatments include laparoscopic or hysteroscopic myomectomy, UAE, and newer options like magnetic resonanceguided high-intensity focused ultrasound, myolysis / radiofrequency ablation and laparoscopic or vaginal occlusion of uterine vessels.
4 UAE for symptomatic leiomyomas was first described by Ravina et al in 1995.
5 In a recent Cochrane review summarising the results of five randomised clinical trials comparing UAE versus surgery (hysterectomy / myomectomy), with a 5-year follow-up, UAE appeared to have an overall patient satisfaction rate similar to hysterectomy and myomectomy, while offering an advantage with regard to a shorter hospital stay and a quicker return to routine activities. There was no significant difference in major complication rate and ovarian failure rate at long-term follow-up. However, UAE is associated with a higher rate of minor complications including nausea, pain and vaginal discharge, and an increased likelihood of requiring surgical intervention within 2 to 5 years of the initial procedure. 6 The principle of UAE is based on the fact that there are enlarged vessels feeding the leiomyoma and there is preferential flow through these vessels early in the embolisation process. The goal is to occlude the vessels of the leiomyoma but not to completely occlude the uterine artery. Three types of regularly calibrated microspheres were introduced over a short time period, subsequently, with increasing usage, as there is concern regarding particle clumping, unpredictable behaviour, and the clinical effectiveness with the use of Contour PVA in UAE. 9 used a sheep model to show that calibrated microspheres behave differently from nonspherical PVA in UAE. PVA particles were associated with more uterine necrosis than calibrated tris-acryl microspheres. Furthermore, PVA particles occluded vessels of a wider range of size than did calibrated TAGM since they form aggregates.
9 PVA was also shown to reduce fertility in sheep models after UAE.
7
To date, there is limited information on the clinical impact of different regularly calibrated microsphere for UAE. A systematic review and meta-analysis of published comparative trials by Das et al 10 showed no evidence of superiority of any embolic agent. When this manuscript was written, only five clinical studies on A-PVAM for UAE had been published. [11] [12] [13] [14] [15] [16] Worthington-Kirsch et al 13 showed that there was no difference in efficacy between A-PVAM and TAGM. Our result is comparable with that by Liaw et 
CONCLUSION
A-PVAM for UAE of leiomyomas in the manner described resulted in a high rate of positive outcome in our study with a limited sample size. However, the efficacy of A-PVAM for UAE is yet to be fully investigated. Future study on its long-term outcome, or a comparative study with other embolic agents would be useful. Interventional radiologists should stay updated of data from studies with new embolic agents.
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